Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Red Tree Venture Capital is an early-stage life science venture firm founded in 2020 and headquartered in Redwood City, California. The firm was established to capitalize on the rich ecosystem of innovation present in the West Coast's leading academic and research institutions. Red Tree closed its inaugural fund, Red Tree Venture Capital Fund I, in 2022, successfully raising $272 million to invest in transformative science.
The firm has quickly positioned itself as a key player in the biotech and healthcare sectors, focusing on companies that address significant unmet medical needs. Red Tree's investment strategy is deeply rooted in its connections with premier institutions such as Stanford University and the University of California system, which provide a steady pipeline of innovative life science companies.
As of now, Red Tree Venture Capital continues to build its portfolio, aiming to support breakthrough science from seed, preclinical, or early clinical stages. The firm’s commitment to early-stage investments allows it to play a crucial role in the development of first-in-class and best-in-class therapeutics.
Red Tree Venture Capital employs a West Coast-centric investment strategy, primarily targeting early-stage companies developing first-in-class and/or best-in-class therapeutics. The firm concentrates on significant unmet needs in oncology, neurology, and immunology. Red Tree aims to provide initial institutional capital to approximately half of the companies it funds, supporting breakthrough science from seed, preclinical, or early clinical stages.
The firm’s investment criteria include a strong emphasis on innovative therapeutic solutions that can address critical gaps in current medical treatments. Red Tree seeks to partner with founders who demonstrate a deep understanding of their respective fields and possess the capability to drive their companies toward successful outcomes. The firm is particularly interested in companies that are connected to leading academic institutions, as these relationships often enhance the potential for groundbreaking advancements in life sciences.
Red Tree Venture Capital has invested in several notable companies connected to premier West Coast institutions, including Stanford University, the University of California, San Francisco, and the University of California, Los Angeles. The firm’s portfolio includes:
These companies exemplify Red Tree's commitment to investing in transformative life science innovations that have the potential to significantly impact patient care and treatment outcomes.
Heath Lukatch, Ph.D.: Co-Founder and Managing Partner. Heath has extensive experience in the life sciences sector, having previously worked at leading venture capital firms and biotech companies. He holds a Ph.D. in a relevant scientific field.
Jennifer Cochran, Ph.D.: Co-Founder and Chief Scientific Advisor. Jennifer brings a wealth of scientific expertise and has a strong background in research and development within the biotech industry. She has held academic positions at prestigious institutions.
Jeremy Caldwell, Ph.D.: Managing Director. Jeremy has a proven track record in venture capital and has led investments in several successful biotech startups. He holds a Ph.D. and has experience in both academia and industry.
To pitch Red Tree Venture Capital, founders should submit their proposals through the contact form available on the firm's website. A comprehensive pitch deck should include details about the team, product, market opportunity, and financial projections.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions through mutual connections are preferred, as they can enhance the likelihood of receiving a timely response.
In 2022, Red Tree Venture Capital successfully closed its inaugural fund, raising $272 million to invest in transformative life science innovations. The firm has been actively sourcing innovative life science companies through its relationships with leading West Coast academic and research institutions.
As of 2023, Red Tree continues to expand its portfolio, focusing on early-stage investments in biotech and healthcare sectors. The firm remains committed to addressing significant unmet medical needs through its strategic investments.
What are Red Tree Venture Capital's investment criteria?
Red Tree focuses on early-stage life science companies that are developing first-in-class and best-in-class therapeutics, particularly in oncology, neurology, and immunology. The firm seeks to address significant unmet medical needs and prefers to provide initial institutional capital to about half of the companies it funds.
How can founders apply or pitch to Red Tree?
Founders can reach out directly through the contact information provided on Red Tree's website. A well-prepared pitch deck that outlines the company's vision, market opportunity, and scientific basis is essential for consideration.
What makes Red Tree different from other venture firms?
Red Tree's unique advantage lies in its strong connections with leading West Coast academic institutions, which provide access to innovative life science companies and cutting-edge research. This focus on transformative science sets Red Tree apart in the venture capital landscape.
What is the geographic scope of Red Tree's investments?
The firm primarily invests in North America, specifically targeting companies based in the United States. This geographic focus allows Red Tree to leverage its relationships with local academic and research institutions.
What is the typical check size for investments made by Red Tree?
While specific check sizes are not disclosed, Red Tree typically invests in early-stage rounds, including pre-seed, seed, seed-plus, and Series A funding stages. The firm aims to provide substantial initial capital to support the growth of its portfolio companies.
What kind of post-investment involvement does Red Tree have?
Red Tree Venture Capital actively engages with its portfolio companies, providing operational support, strategic guidance, and access to its network of industry experts and academic resources. This involvement is designed to help companies navigate the challenges of early-stage development.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.